Photo: open.spotify.com
Apr 21, 2026, 14:44
Continuing the Conversation on Factor VIII – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD), shared a post on LinkedIn:
”Continuing the conversation on Factor VIII!
As innovations such as emicizumab, rebalancing agents, and gene therapy continue to transform care, what is the place of FVIII today, and where is it heading next?”
Stay updated with Hemostasis Today.
-
Apr 21, 2026, 14:50WFH Volunteer Awards
-
Apr 21, 2026, 14:36Chokri Ben Lamine: 50 Pearls Credits on How is Breakthrough Thrombosis in Patients with Cancer Being Treated
-
Apr 21, 2026, 14:26Wolfgang Miesbach: Rebalancing Agents in Haemophilia Are Not “Set and Forget” – Key Insights from WFH 2026
-
Apr 21, 2026, 13:50ITP Care in Your Language – ITP Support Association
-
Apr 21, 2026, 13:23Moustafa Abdou: Artificial Intelligence in Hematology
-
Apr 21, 2026, 13:08Eric Arzubi: The Hidden Crisis in Healthcare Ownership and Leadership
-
Apr 21, 2026, 12:50Chokri Ben Lamine: Clinical Insights into Glanzmann Thrombasthenia and Heavy Menstrual Bleeding
-
Apr 21, 2026, 12:11Sam K. Saha: Stroke Recovery Cannot Wait Until Discharge
-
Apr 21, 2026, 12:09Harshmal Mamlekar: Inspiring Opportunity to Engage with Leaders Shaping the Future of Hematology